The Evidence-Based Medicine Consultancy Ltd responded on Trial Site News to the 22nd March EMA Statement on Ivermectin for COVID-19.
In summary: It is time for regulatory authorities to recognize that ivermectin’s effectiveness in covid-19 has already been demonstrated and that its general safety profile is extremely well-known. In a pandemic situation, regulators should approve this very safe medicine for routine use, at the clinical discretion of any licensed medical practitioner. Further delay can lead only to further unnecessary loss of life.
Evidence-Based Medicine Consultancy Ltd, Trial Site News, 25th March 2021
Read the BiRD rebuttal to the European Medicines Agency’s pronouncement on ivermectin (6 languages):-
Translation